1	Development and validation of DNA Methylation scores in two European cohorts augment
2	10-year risk prediction of type 2 diabetes
3	Yipeng Cheng ^{1,2} , Danni A Gadd ¹ , Christian Gieger ^{3,4,5} , Karla Monterrubio-Gómez ⁶ , Yufei
4	Zhang ¹ Imrich Dorta ¹ Michael I Stem ⁷ Natalia Szlachetka ⁷ Eugenii Labzaey ⁷ Nicela
4	Zhang, Imrich Berta, Michael J Stam, Natana Sziachetka, Evgenn Lodzaev, Nicola
5	Wrobel ⁸ , Lee Murphy ⁸ , Archie Campbell ¹ , Cliff Nangle ¹ , Rosie M Walker ^{1,9} , Chloe Fawns-
6	Ritchie ^{10,1} , Annette Peters ^{4,5,11} , Wolfgang Rathmann ^{12,5} , David J Porteous ¹ , Kathryn L Evans ¹ ,
7	Andrew M McIntosh ¹³ , Timothy I Cannings ¹⁴ , Melanie Waldenberger ^{3,4} , Andrea Ganna ² ,
8	Daniel L McCartney ¹ , Catalina A Vallejos ^{6,15,*} , Riccardo E Marioni ^{1,*}
9 10	¹ Centre for Genomic and Experimental Medicine, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, EH4 2XU, UK.
11	² Institute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland
12 13	³ Research Unit Molecular Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health (GmbH), Neuherberg, Germany
14 15	⁴ Institute of Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health (GmbH), Neuherberg, Germany
16	⁵ German Center for Diabetes Research (DZD), München-Neuherberg, Germany
17 18	⁶ MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, EH4 2XU, UK.
19	⁷ School of Informatics, University of Edinburgh, Edinburgh, EH8 9AB, UK
20 21	⁸ Edinburgh Clinical Research Facility, University of Edinburgh, Western General Hospital, Edinburgh, UK
22 23	⁹ Centre for Clinical Brain Sciences, University of Edinburgh, Chancellor's Building, 49 Little France Crescent, Edinburgh BioQuarter, Edinburgh, EH16 4SB, UK
24	¹⁰ Department of Psychology, University of Edinburgh, Edinburgh, EH8 9JZ, UK
25 26	¹¹ DZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany
27 28	¹² Institute for Biometrics and Epidemiology, German Diabetes Center, Leibniz Institute for Diabetes Research at Heinrich Heine University, Düsseldorf, Germany
29 30	¹³ Division of Psychiatry, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK
31	¹⁴ School of Mathematics, University of Edinburgh, Edinburgh, EH9 3FD, UK
32	¹⁵ The Alan Turing Institute, London, UK NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

- 34 *Corresponding authors:
- 35 Names: Riccardo Marioni and Catalina Vallejos
- 36 Contact Details: riccardo.marioni@ed.ac.uk and catalina.vallejos@ed.ac.uk

37 Abstract

Type 2 diabetes mellitus (T2D) presents a major health and economic burden that could be 38 alleviated with improved early prediction and intervention. While standard risk factors have 39 shown good predictive performance, we show that the use of blood-based DNA methylation 40 information leads to a significant improvement in the prediction of 10-year T2D incidence risk. 41 Previous studies have been largely constrained by linear assumptions, the use of CpGs one-at-42 a-time, and binary outcomes. We present a flexible approach (via an R package, *MethylPipeR*) 43 based on a range of linear and tree-ensemble models that incorporate time-to-event data for 44 prediction. Using the Generation Scotland cohort (training set n_{cases}=374, n_{controls}=9,461; test 45 set n_{cases}=252, n_{controls}=4,526) our best-performing model (Area Under the Curve (AUC)=0.872, 46 Precision Recall AUC (PRAUC)=0.302) showed notable improvement in 10-year onset 47 48 prediction beyond standard risk factors (AUC=0.839, PRAUC=0.227). Replication was observed in the German-based KORA study (n=1,451, $n_{cases} = 142$, $p=1.6x10^{-5}$). 49

50 Introduction

Diabetes mellitus is one of the most prevalent diseases in the world and a leading cause of 51 mortality. Around half a billion people live with diabetes worldwide, with type 2 diabetes 52 (T2D) making up about 90% of these cases [1]. Individuals with diabetes can suffer from 53 debilitating complications including nerve damage, kidney disease and blindness [2]. The 54 disease also increases the future risk of dementia and cardiovascular disease [3], with recent 55 studies highlighting obesity and T2D as risk factors for COVID-19 disease severity and ICU 56 admission [4]. Furthermore, risk of complications increases over time and is exacerbated if 57 blood-glucose levels are poorly managed. Despite developments in the way T2D can be 58 managed for patients, these treatments are reactive, focusing on patients that have already been 59 diagnosed. Early intervention with metformin or lifestyle changes have been shown to delay 60 61 onset of T2D, although they did not reduce the risk of all-cause mortality [5].

Beyond public health costs, T2D also presents a substantial financial burden to the NHS, with
estimated annual spending of £10 billion on diabetes in the UK. Around 80% of these costs are
for treatment of complications, many of which are preventable with early intervention [6].

65 While the mechanisms of insulin resistance in T2D are well-known, the interactions between genetic and environmental factors that increase T2D susceptibility are less understood. 66 Previous T2D risk prediction models have used a range of health risk factors [7]. However, 67 68 these have not utilised epigenetic information. Epigenetics is the study of heritable changes to DNA that do not modify its nucleotide sequence. A commonly studied form of this is DNA 69 methylation (DNAm), whereby methyl groups are attached to the DNA molecule - most 70 71 commonly to the 5-carbon on a cytosine in a cytosine-guanine pair (CpG). Due to its involvement with gene expression and gene-environment interactions, DNAm can provide 72 dynamic predictive information for disease risk for an individual. For example, Epigenetic 73

74 Scores (EpiScores) built via penalised regression models have been used to show that weighted linear CpG predictors can explain a substantial proportion of phenotypic variance (R^2) of 75 modifiable health factors including body mass index (BMI) (12.5%), HDL cholesterol (15.6%) 76 77 and smoking status (60.9%) [8]. Blood-based DNAm is of particular interest in predictive modelling and biomarker development due to its comparatively non-invasive sampling 78 procedure. EpiScores have also shown the ability to explain up to 58% of variance in plasma 79 protein levels are associated with a number of incident diseases including T2D and several 80 comorbidities [9]. Epigenome-wide association studies (EWAS) have identified a number of 81 82 CpG sites significantly associated with T2D [10-14] as well as related risk factors such as cardiovascular disease [15] and obesity [16, 17]. While these provide some predictive 83 performance for T2D prevalence, incident T2D has been less well studied. One such EWAS 84 85 with 563 cases and 701 controls identified 18 CpGs associated with incident T2D but did not consider any prediction models [10]. Given that preventative lifestyle changes have been 86 shown to effectively reduce T2D onset [18], prediction of T2D incidence years ahead of time 87 would be greatly beneficial in stratifying populations so those at high risk can be monitored 88 and treated with early interventions. 89

90 Currently, most studies generating DNAm predictors consider marginal CpG effects or assume 91 only linear additive effects between CpGs. The use of predictive models that can incorporate 92 both interaction and non-linear effects could capture more complex relationships between 93 variables, resulting in greater prediction accuracy. Therefore our study aims to evaluate both 94 the additional predictive benefit that DNAm can provide for 10-year T2D risk and the 95 applicability of linear and tree-ensemble survival models.

Here, we use one of the world's largest studies with paired genome-wide DNAm and data
linkage to electronic health records (EHR), Generation Scotland (n=14,613, n=626 incident
T2D cases over 15 years of follow-up), to develop and validate epigenetic EpiScores for T2D.

We show the added contribution of these EpiScores to prediction over and above standard riskfactors e.g. age, sex and BMI and externally validate these results in the KORA S4 cohort.

101

102 Methods

103 Reporting of Analysis Pipeline and Results

To enhance reproducibility, the analysis pipeline and results presented in this study have been
reported via the TRIPOD checklist [19] (Supplementary File 1).

106 *Generation Scotland*

Blood-based DNAm and linked health data were obtained from Generation Scotland [20], a 107 family-structured population-based cohort. The cohort consists of 23,960 volunteers across 108 Scotland aged 18-99 years at recruitment (between 2006 and 2011), of whom over 18,000 109 currently have genome-wide DNAm data available (Illumina EPIC array). In DNAm quality 110 control, CpG sites were filtered by removing those with low bead count in \geq 5% of samples or 111 112 a high detection p-value (>0.05) in more than 5% of samples. Probes on X and Y chromosomes were also removed. Samples were filtered by removing those with a mismatch between 113 predicted and recorded sex or $\geq 1\%$ of CpGs with detection p-value > 0.05. Missing CpG values 114 were mean-imputed. To enable the predictors to be applied to existing cohort studies with older 115 Illumina array data, CpGs were filtered to the intersection of the 450k and EPIC array sites 116 (n=453,093 CpGs). 117

This study considered DNAm data from three large subsets of the GS cohort, with 5,087 (Set 1), 4,450 (Set 2) and 8,877 (Set 3) individuals. Processing took place in 2017, 2019 and 2021 respectively. Set 1 and Set 3 included related individuals within and between each set while all individuals in Set 2 were unrelated to each other and to individuals in Set 1 (genetic relationship

matrix (GRM) threshold <0.05). In our experiments, the training set consisted of Sets 2 and 3 combined and Set 1 was used as the test set. To avoid the presence of families with individuals across both the training and test set, any individuals in the training set from the same family as an individual in the test set were excluded from the analysis ($n_{excluded}=3,138$).

Participant health measures including age, BMI, sex, self-reported hypertension and family (parent or sibling) history of T2D were taken at baseline (DNAm sampling) via questionnaire. BMI was calculated as the individual's weight in kilograms divided by the square of their height in metres. Missing values in the Set 1 health measures were treated as missing-completely-atrandom and the corresponding individuals were excluded ($n_{Set 1}=99$). This was not performed in Sets 2 and 3 as the health measures were used for incremental modelling (Set 1 only).

Disease cases were ascertained through data linkage to NHS Scotland health records consisting 132 of hospital (ICD-10 codes) and GP records (Read2 codes). Prevalent cases were identified from 133 a baseline questionnaire (self-reported) or from ICD-10/Read2 codes dated prior to baseline 134 and removed from the dataset. Type 1 and juvenile cases were treated as control observations. 135 A total of 757 incident cases were observed over the follow up period (from recruitment date 136 to 01/2022) and after preprocessing, 626 cases remained. Mean time-to-T2D-onset was 5.9, 5.4 137 and 6.0 years for Sets 1, 2 and 3 respectively, with ranges of 0.2 - 14.8 (Set 1), 0.2 - 14.8 (Set 138 2) and 0.1-14.8 (Set 3) years. In GP record-derived cases, 81% of cases had a C10F. "type 2 139 diabetes mellitus" code; 12% had a C10.. "diabetes mellitus" code and 4% had a C109. "Non-140 insulin dependent diabetes mellitus" code. The full list of included and excluded terms are 141 given in Supplementary Table 1. 142

143

144 *Composite Protein EpiScore*

A composite protein EpiScore model for incident T2D was trained using a set of 109 protein EpiScores previously shown to associate with a range of incident diseases [9]. For each protein, the EpiScore was calculated for each subject in the training and test sets. A Cox proportionalhazards (Cox PH) lasso model was fit to the training set with the 109 protein EpiScores (scaled within set to mean of 0 and variance 1) as features. The linear predictor from the Cox PH lasso model was then used as the composite protein EpiScore in the incremental test set model.

151

152 Direct EpiScore

The direct EpiScore Cox PH lasso model for incident T2D was fit to the DNAm data in the training set. Due to memory limitations in the model fitting R package (glmnet [21]), the CpGs were filtered to the 200,000 sites with highest variance. The linear predictor from the Cox PH lasso model was then used as the direct EpiScore in the incremental test set modelling. For tree ensemble models, the Cox PH lasso-selected CpGs were used as input and the 10-year onset risk was subsequently used as the direct EpiScore.

159

160 Outcome Definition for 10-Year Onset Prediction

Linkage to NHS Scotland health records provided dates for disease diagnoses from which ageat-onset was calculated. Along with age at baseline (DNAm sampling), these were used to calculate the time-to-event, measured in years, for each individual. For incident T2D cases and controls, time-to-event was defined as the time from baseline to disease onset and censoring, respectively. Controls were censored at the latest date of available GP records (09/2020).

166 While all models were trained as survival models, our primary prediction outcome was incident

167 T2D diagnosis within 10 years. Therefore, predictions on the test set were calculated using the

168 10 year onset probability (one minus survival probability). When calculating binary outcome 169 metrics, cases with time-to-event (TTE) > 10 were treated as controls. These metrics included 170 confusion matrices, area under the receiver operating characteristics curve (AUC) and area 171 under the precision-recall curve (PRAUC). After preprocessing and case thresholding (TTE > 172 10), there were 218 cases and 4,560 controls in the test set.

The numbers of individuals/cases and controls after each preprocessing step are shown in
Supplementary Figure 1.

175

176 Incremental Modelling

Composite protein EpiScores and direct EpiScores were generated in the training dataset using 177 different machine learning methods, via the *MethylPipeR* package (Figure 1), before being 178 applied to the test set in an incremental modelling approach (further detail in Supplementary 179 180 Methods). In the test set, a (null) risk factors-only model was defined via a Cox PH model for T2D with age, sex, BMI, self-reported hypertension, and self-reported family (sibling or 181 parental) history of diabetes as predictors. A multitude of risk factors have been used in 182 183 previous T2D risk prediction tools, a majority of which include the set that we have used in this study. While additional risk factors, such as waist-hip ratio, may also be relevant [7], we 184 selected the null model covariates based on those used in the Diabetes UK type 2 diabetes 185 'Know Your Risk' tool to compare our results to an existing widely utilised tool. This was with 186 the exception of ethnicity, due to the relative homogeneity of the GS cohort. These also closely 187 match the top risk factors identified in a systematic review of previous T2D risk predictors (see 188 Figure 2 in ref. [7]). 189

190

191 Penalised Regression Predictors

Since the number of CpGs ($n_{CpG}=200,000$) was much greater than the number of rows in the training set (n=9,835 after preprocessing), a regularisation method was required to reduce overfitting of the Cox PH regression models.

Penalised regression models reduce overfitting by applying a regularisation penalty in the model fitting process. This forces regression parameters to remain small, or possibly to shrink them to zero. The latter allows the method to be used for variable selection, by keeping only the variables with resulting non-zero coefficients.

199 Lasso penalisation was fit to the training set DNAm and protein EpiScores using glmnet [21,

200 22] via *MethylPipeR* with the best shrinkage parameter (λ) chosen by 9-fold cross-validation.

201

202 Tree Ensemble Models

Tree ensembles are non-parametric models capable of estimating complex functions using a 203 set of decision trees. Two tree ensemble approaches were used: random survival forest (RSF) 204 [23] and survival Bayesian Additive Regression Trees (sBART) [24]. Random forest [25] is an 205 ensemble machine learning model that estimates a function by averaging the output from a set 206 of independently trained decision trees. During model fitting, each tree is built using a different 207 subset of the variables from the training set to prevent individual trees from overfitting to the 208 whole dataset. sBART is a non-parametric method that estimates a function as a sum over a set 209 of regression trees. sBART incorporates the ability to model both additive and interaction 210 effects and has shown high predictive performance in comparison with similar methods [24, 211 212 26].

RSF and sBART were fit to the training set using R packages randomForestSRC (version
2.11.0) [27] and BART (version 2.9) [28] respectively, via *MethylPipeR*. Details on
hyperparameter selection are given in Supplementary Methods.

Due to computational limitations and probable overfitting in using the tree ensemble models on all CpGs in the dataset, variable pre-selection was based on the coefficients in the penalised Cox PH models. Each tree-ensemble model was evaluated with the features corresponding to non-zero coefficients from the Cox PH lasso model.

220

221 Evaluating Predictive Performance

Survival models can be used to predict the risk of incident T2D for an arbitrary prediction
period. Here we focus on classification performance for the binary outcome defined by 10-year
T2D incidence. EpiScores were calculated as one minus 10-year survival probabilities and the
binary outcomes were calculated by truncating observed TTE at 10-years (see *Outcome Definition for 10-Year Onset Prediction*).

AUC and PRAUC were calculated as measures of predictive performance as the discrimination 227 228 threshold was varied. PRAUC is more informative in situations where there is a class imbalance in the test set [29]. Additionally, binary classification metrics consisting of sensitivity (recall), 229 230 specificity, positive predictive value (PPV/precision) and negative predictive value (NPV) 231 were calculated. These metrics require selection of a discrimination threshold to assign positive/negative class predictions and have varying behaviour as this threshold is altered. 232 Therefore, each of the metrics were calculated at a range of thresholds between 0-1 in 233 234 increments of 0.1.

Model calibration was examined by comparing predicted probabilities with actual case/control proportions. The test data was sorted by predicted probability and divided into bins; the mean predicted probability and the proportion of cases was calculated for each bin.

239 Selected-CpG Comparison with EWAS Catalog

The CpG sites selected by the Cox PH lasso were queried in the EWAS Catalog [30] to identify traits that have previously been linked to these sites. The EWAS catalog is a database allowing users to search EWAS results from existing literature. We performed a tissue-agnostic query using the selected CpGs and filtered results to those with an epigenome-wide significance threshold of P < 3.6 x 10⁻⁸ in studies with a sample size > 1,000 [31]. Almost all (739 out of 742; 99.6%) of the post-filter results were from blood-based studies. The remaining results were from saliva and prefrontal cortex-based studies.

247

248 Validation in KORA S4

The Cox PH lasso model using the direct EpiScore was applied to the KORA S4 cohort [32]. 249 This cohort consisted of 1,451 individuals in southern Germany, aged 25-74 years. Cohort 250 summary details are shown in Supplementary Table 2. Individuals with missing values in 251 the health measures were removed from the dataset. Missing CpG values in the DNAm data 252 were mean-imputed. Similar to the approach in the Generation Scotland test set, an EpiScore 253 254 was computed for each individual in the KORA dataset. Evaluation was then performed using an incremental modelling approach. Additional cohort and methods details (such as the 255 outcome definition, follow-up period and preprocessing numbers) are provided in 256 Supplementary methods. 257

258

259 EpiScore Prediction of Ongoing Symptomatic COVID-19/Hospitalisation

The subset of the Generation Scotland cohort with reported COVID-19 infection (clinicallydiagnosed or positive test from linked test data), who had also participated in the CovidLife

study [33] were used for prediction of ongoing symptomatic COVID-19 and hospitalisation from COVID-19 (n=713). Ongoing symptomatic COVID-19 cases were defined here as individuals with self-reported symptoms lasting \geq 4 weeks [34]. Hospitalisation cases were defined as hospital admissions with accompanying ICD10 codes U07.1 (confirmed COVID-19 test) and U07.2 (clinically diagnosed), derived from the Scottish Morbidity Records (SMR01). Details of the method and summary statistics are shown in **Supplementary methods** and **Supplementary Table 3**.

269

270 **Results**

After preprocessing, the mean time-to-onset of T2D was 5.7 and 5.9 years for the training (n=374 cases) and test (n=252 cases) sets, respectively. Mean age-at-onset was also similar between the training and test set at 61.2 and 60.4 years and the mean BMI for cases (at baseline) was 31.7 and 32.2 kg/m². The full set of cohort summary details for cases and controls in both sets are shown in **Table 1**. The machine learning prediction pipeline of the *MethylPipeR* package is shown in **Figure 1**.

277

278 Null Model for the Incremental Modelling Approach

A Cox PH model in the test set with age, sex, BMI, self-reported hypertension, and family
history of diabetes as predictors yielded good classification metrics: AUC=0.839,
PRAUC=0.227.

282

283 Incremental model using Direct EpiScore derived using Cox PH lasso, RSF and sBART

284 In the risk factors + direct EpiScore test set model, Cox PH lasso performed the best, showing an AUC and PRAUC of 0.870 and 0.299, respectively (p=3.6x10⁻²⁷ for the EpiScore 285 coefficient). This corresponds to an increase of 3.1% and 7.2% over the standard risk factors 286 287 model.

Overall, the tree-ensemble models used for the direct EpiScore resulted in lower performance 288 compared to Cox PH lasso. AUC values for RSF and sBART were 0.852 and 0.840 and 289 PRAUC values were 0.247 and 0.230, respectively (Supplementary Table 4). P-values for the 290 EpiScore coefficients and ROC curves for all models are given in (Supplementary Table 5). 291

Incremental model using Composite Protein EpiScore derived using Cox PH lasso 292

The composite protein EpiScore showed good performance with AUC and PRAUC of 0.864 293

294 smaller for the composite protein EpiScore compared to the direct EpiScore but still a notable 295

and 0.270, respectively (EpiScore coefficient $p=1.61 \times 10^{-18}$). The increase in PRAUC was

improvement over using risk factors only. 296

297

Incremental model using Composite Protein and Direct EpiScores 298

The full model (risk factors + composite protein EpiScore + direct EpiScore) with a Cox PH 299 lasso direct EpiScore gave an AUC and PRAUC of 0.872 and 0.302 respectively. The full 300 models with RSF- and sBART-derived direct EpiScores showed AUCs of 0.866 and 0.864, 301 respectively. The corresponding PRAUC values were 0.273 and 0.270. Therefore, the best 302 overall model used direct and composite protein EpiScores from Cox PH lasso models. The 303 ROC and PR curves for the full models and risk factor only model are shown in Figure 2. 304

305

306 Binary Classification Metrics and Model Calibration

307 Supplementary Table 6 shows how confusion matrix metrics vary for the null (risk factors only) model and the Cox PH lasso model across a range of probability classification thresholds. 308 As expected, as the classification probability threshold is increased, sensitivity and NPV 309 310 decrease while specificity increases. The effects of these differences on the number of true positives and true negatives are illustrated in Figure 3. The two models also show differences 311 in their calibration plots (Supplementary Figure 2). In addition, the difference in number of 312 correctly classified individuals between the two models are given. These are calculated 313 assuming, arbitrarily, a 10-year incidence rate of 33%, for example, in a scenario where high-314 risk individuals have been selected for screening. 315

316

317 Selected CpGs

318 The Cox PH lasso model assigned non-zero coefficients to 145 CpGs (Supplementary Table

319 7). After filtering the EWAS Catalog by p-value ($p < 3.6 \times 10^{-8}$) [31] and sample size (n > 1,000),

320 119 (82%) of the model-selected CpGs were present. These CpGs corresponded to 742 entries

and showed epigenome-wide associations with traits including: serum HDL cholesterol, serum

triglycerides, smoking, C-reactive protein, BMI and age (Supplementary Table 8).

323

324 Selected Protein EpiScores

The composite protein EpiScore Cox PH lasso model assigned non-zero coefficients to 46 protein EpiScores. Details on the corresponding proteins and genes are given in **Supplementary Table 9**. Out of the selected protein EpiScores, 21 have previously shown associations with incident T2D [9].

330 Validation in KORA S4

Prediction of incident diabetes in the KORA S4 cohort using the Cox PH lasso model showed good replication of direct EpiScore performance ($p=1.6x10^{-5}$) with increases of 1.6% and in absolute terms above the null model values for both AUC and PRAUC. Further details are provided in **Supplementary Table 10**.

335

336 EpiScore Prediction of Ongoing Symptomatic COVID-19/Hospitalisation

In all models, incident T2D was predictive of hospitalisation with COVID-19 infection.
However, neither the composite-protein nor the direct EpiScore were predictive of the same
outcome (Supplementary Table 11). Additionally, neither the EpiScores nor incident T2D
were predictive of ongoing symptomatic COVID after COVID-19 infection.

341

342 Discussion

Utilising a large cohort with genome-wide epigenetic data and health records linkage to 343 longitudinal primary and secondary care, we have shown that DNAm-based predictors 344 augment standard risk factors in the prediction of incident type 2 diabetes. The best model with 345 traditional risk factors yielded an AUC of 0.839 compared to 0.872 when DNAm was also 346 considered and the PRAUC increased from 0.227 to 0.305. Using a variety of linear and non-347 linear survival models, we showed that overall, the Cox PH lasso model produced the most 348 predictive direct EpiScore. A composite protein EpiScore also notably increased predictive 349 performance. The direct EpiScore also showed good external validation performance in the 350 KORA S4 cohort. Beyond the T2D analysis presented here, we have developed the 351 MethylPipeR R package, along with a user-interface MethylPipeR-UI, to facilitate reproducible 352

353 machine learning time-to-event and binary prediction using DNAm or other types of high-354 dimensional omics data.

Determining a 'best' model is complicated and depends on the trade-off that a user wishes to 355 make. Here, we optimised AUC and PRAUC but binary classification metrics vary by method 356 and/or classification threshold. When using classifiers in clinical settings, decisions need to be 357 made about the number of patients that can be recommended for intervention as well as the 358 acceptable proportion of false positives and false negatives. We showed an increase in correct 359 identification of positives/negatives at varying probability thresholds when adding direct and 360 composite EpiScores above standard risk factors. For instance, given an (arbitrary) incidence 361 rate of 33% (commonly used as a cut-off for high-risk of T2D) [35] over 10 years in a sample 362 of 10,000 individuals, our best model would correctly classify an additional 448 individuals 363 compared to the risk factors only model at a threshold of 0.2 (Supplementary Table 6). Given 364 the costs of treating T2D-related complications, our study gives evidence for possible benefits 365 of EpiScores on public health that could also alleviate the financial burden to the NHS. In 366 addition, an assessment of calibration is also critical [36]. Investigation of these related criteria 367 could assist in deciding an optimal threshold given clinical constraints and provide a more 368 369 comprehensive assessment of model predictions than AUCs or metrics at the commonlyutilised threshold of 0.5. 370

Several CpGs from the direct EpiScore were previously identified as epigenome-wide significant correlates of traits commonly linked to T2D [14, 17, 37-41]. Future work could investigate overlap between these and time-to-event EWAS studies. Further studies could also include DNAm predictors for traditional risk factors that are included in the null model, such as BMI [8].

376 Limitations include the relatively small number of disease cases in the dataset, the limited hyperparameter optimisation performed for sBART and the relatively simple variable pre-377 selection method for tree-ensemble methods. Given the lower performance of these methods 378 compared to the best models in this study, there is potential for additional improvement in 379 predictive performance with further investigation of more advanced feature (pre-)selection. 380 This is particularly important when we consider that the pre-selection step utilised linear 381 models prior to the non-linear model fitting. The model fitting and pre-selection were also 382 performed using the same training set which may have introduced issues associated to post-383 384 selection inference [42, 43]. In addition, factors such as overfitting, related individuals in the test set and batch effects between the three rounds of DNAm data processing may all have an 385 effect on test-set AUC. Finally, a small proportion of the linkage codes used to define diabetes 386 387 included broad terms that were non-specific to T2D; however, late age of onset in these individuals meant there was a high likelihood that they had developed T2D. EpiScores for 388 T2D-associated proteins have also been shown to replicate incident T2D-protein associations 389 390 within this sample [9] suggesting that the case definitions we use capture biological signals relevant to T2D. 391

There are numerous strengths to our study. Firstly, the models used capture relationships between CpGs as well as time-to-event information, which is not possible using traditional EWAS methods. Secondly, data linkage to health care measures provided comprehensive T2D incidence data in a very large cohort study, Generation Scotland. Validation performance in the KORA cohort also strengthened evidence for the applicability of the models to other populations. Finally, the R package, *MethylPipeR*, encourages reproducibility and allows others to develop similar predictors on new data with minimal setup.

In conclusion, we have demonstrated the potential for DNA methylation data to provide notableimprovement in predictive performance for incident T2D, as compared to traditional risk

401 factors (age, sex, BMI, hypertension, and family history). We evaluated different models with
402 a systematic approach and presented a framework with the ability to generalise to other traits
403 and datasets for training and testing predictors in future studies.

404

405 **Declarations**

406 *Ethics approval and consent to participate*

All components of Generation Scotland received ethical approval from the NHS Tayside
Committee on Medical Research Ethics (REC Reference Number: 05/S1401/89). Generation
Scotland has also been granted Research Tissue Bank status by the East of Scotland Research
Ethics Service (REC Reference Number: 20-ES-0021), providing generic ethical approval for
a wide range of uses within medical research.

The KORA studies were approved by the Ethics Committee of the Bavarian Medical Association (Bayerische Landesärztekammer; S4: #99186) and were conducted according to the principles expressed in the Declaration of Helsinki. All study participants gave their written informed consent.

416

417 Availability of Data and Material

According to the terms of consent for Generation Scotland participants, access to data must be reviewed by the Generation Scotland Access Committee. Applications should be made to access@generationscotland.org.

421 All code is available with open access at the following Gitlab repository:
422 https://github.com/marioni-group

423 *MethylPipeR* (version 1.0.0) is available at: <u>https://github.com/marioni-group/MethylPipeR</u>

424 *MethylPipeR-UI* is available at: <u>https://github.com/marioni-group/MethylPipeR-UI</u>

The informed consents given by KORA study participants do not cover data posting in public databases. However, data are available upon request from KORA Project Application Self-Service Tool (https://epi.helmholtz-muenchen.de/). Data requests can be submitted online and are subject to approval by the KORA Board.

429

430 *Competing Interests*

R.E.M has received a speaker fee from Illumina and is an advisor to the Epigenetic Clock
Development Foundation. A.M.M has previously received speaker fees from Janssen and
Illumina and research funding from The Sackler Trust. L.M has received payment from
Illumina for presentations and consultancy. All other authors declare no competing interests.

435

436 Acknowledgements

This research was funded in whole, or in part, by the Wellcome Trust [104036/Z/14/Z,
108890/Z/15/Z, 216767/Z/19/Z]. For the purpose of open access, the author has applied a
CC BY public copyright licence to any Author Accepted Manuscript version arising from
this submission.

Generation Scotland received core support from the Chief Scientist Office of the Scottish Government Health Directorates (CZD/16/6) and the Scottish Funding Council (HR03006) and is currently supported by the Wellcome Trust (216767/Z/19/Z). DNA methylation profiling of the Generation Scotland samples was carried out by the Genetics Core Laboratory at the Edinburgh Clinical Research Facility, Edinburgh, Scotland and was funded by the Medical

446 Research Council UK and the Wellcome Trust (Wellcome Trust Strategic Award "STratifying Resilience and Depression Longitudinally" (STRADL; Reference 104036/Z/14/Z). The DNA 447 methylation data assayed for Generation Scotland was partially funded by a 2018 NARSAD 448 Young Investigator Grant from the Brain & Behavior Research Foundation (Ref: 27404; 449 awardee: Dr David M Howard) and by a JMAS SIM fellowship from the Royal College of 450 Physicians of Edinburgh (Awardee: Dr Heather C Whalley). Y.C. is supported by the 451 University of Edinburgh and University of Helsinki joint PhD program in Human Genomics. 452 D.A.G. is supported by funding from the Wellcome Trust 4-year PhD in Translational 453 454 Neuroscience-training the next generation of basic neuroscientists to embrace clinical research [108890/Z/15/Z]. C.A.V. is a Chancellor's Fellow funded by the University of Edinburgh. 455 D.L.Mc.C. and R.E.M. are supported by Alzheimer's Research UK major project grant ARUK-456 457 PG2017B-10. R.E.M. is supported by Alzheimer's Society major project grant AS-PG-19b-010. 458

459 Recruitment to the CovidLife study was facilitated by SHARE- the Scottish Health Research460 Register and Biobank.

461 SHARE is supported by NHS Research Scotland, the Universities of Scotland and the Chief462 Scientist Office of the Scottish Government.

463 The KORA study was initiated and financed by the Helmholtz Zentrum München – German 464 Research Center for Environmental Health, which is funded by the German Federal Ministry 465 of Education and Research (BMBF) and by the State of Bavaria. Furthermore, KORA research 466 has been supported within the Munich Center of Health Sciences (MC-Health), Ludwig-467 Maximilians-Universität, as part of LMUinnovativ and is supported by the DZHK (German 468 Centre for Cardiovascular Research). The KORA study is funded by the Bavarian State

- 469 Ministry of Health and Care through the research project DigiMed Bayern (www.digimed-
- 470 bayern.de).

471 Supplementary Methods

472 MethylPipeR and MethylPipeR-UI

The analysis pipeline was implemented via a new R package, MethylPipeR, along with 473 accompanying user interface, for systematic and reproducible development of complex trait 474 and incident disease predictors. *MethylPipeR* provides functionality for tasks such as model 475 fitting, prediction and performance evaluation as well as automatic logging of experiments and 476 trained models. This is complemented by MethylPipeR-UI which provides an interface to the 477 R package functionality while removing the need to write scripts. While MethylPipeR was 478 applied to incident T2D prediction with DNA methylation in our experiments, the package is 479 designed for generalised development of predictive models and is applicable to a wide range 480 of omics data and target traits. MethylPipeR and MethlyPipeR-UI are publicly available at 481 482 https://github.com/marioni-group/MethylPipeR and https://github.com/marionigroup/MethylPipeR-UI respectively. Supplementary Figure 3 shows an example from the 483 MethylPipeR-UI interface including functionality such as data upload, specification of model 484 options and visualisation of model diagnostics. 485

486

487 Methylation Risk Scores and Incremental Modelling

Composite protein EpiScore models were fit to the training set using 109 protein EpiScores as features [9]. This trained model was used to create a composite protein EpiScore for each individual in the test set. Similarly, direct predictors were fit to the training set using 200,000 CpGs as features and used to create a direct EpiScore for each test set individual.

The following Cox PH models were then fit to the test set to assess the difference in metrics such as the area under the curve (AUC) and area under the precision-recall curve (PRAUC): a risk factors only model; risk factors + protein EpiScore; risk factors + direct EpiScore and a

- full model (risk factors + protein EpiScore + direct EpiScore). To obtain 10-year survival
 probabilities in the test set, the cumulative baseline hazard at t=10 was calculated for each
 model using the Breslow estimator [44].
- 498 *Calculating Predictions*
- 499 To obtain predictions from the incremental models, the following should be applied.

500 Direct EpiScore

For the Cox lasso model, the direct EpiScore can be obtained by summing over the CpG values
weighted by their corresponding coefficients (for all non-zero coefficients), as given in
Supplementary Table 12.

504
$$Direct \ EpiScore = \beta_1 CpG_1 + \beta_2 CpG_2 + \dots + \beta_p CpG_p$$

For sBART and RSF, the direct EpiScore requires use of the model object to obtain predictions
on new data. These can be found in https://github.com/marioni-group/ and utilised with *MethylPipeR*'s predict function.

509 The composite protein EpiScore can be obtained by summing over the protein EpiScores 510 weighted by their corresponding coefficients (for all non-zero coefficients), as given in

511 Supplementary Table 12.

512 Composite Protein EpiScore =
$$\beta_1 PES_1 + \beta_2 PES_2 + \dots + \beta_q PES_q$$

513 where q is the number of protein EpiScores with a non-zero coefficient.

Each protein EpiScore is calculated as the sum over CpG values weighted by their corresponding coefficients (for all non-zero coefficients); the coefficients for each of these can be found in the supplementary materials in Gadd et al. [9]

517 Incremental Cox PH

The linear predictor in an incremental Cox PH model can be calculated by multiplying the relevant EpiScores and risk factors by their corresponding coefficient, given in **Supplementary Table 12**. The cumulative baseline hazard is calculated using the basehaz.gbm function in the gbm R package version 2.1.8 [45]. The 10-year survival probabilities can then be calculated as $S(t) = exp[-(\Lambda_0(t))]^{exp(l)}$ at t = 10, where $\Lambda_0(t)$ is the cumulative baseline hazard and *l* is the linear predictor. The 10-year onset probability is therefore 1 - S(10).

524 Penalised Cox Proportional-hazards Regression

Since the number of features (200,000) was much greater than the number of individuals in the
training set (=9,835 after data preprocessing), a regularisation method was required to reduce
overfitting of the Cox PH models.

528 Cox PH models with lasso penalisation was fit to the training set using glmnet (version 4.1-1)
529 [21, 22] via *MethylPipeR*.

Hyperparameter optimisation and cross validation (CV) were used to select the λ that 530 minimised the partial-likelihood for each Cox PH model corresponding to the minimum partial-531 likelihood. The training set was divided equally into nine partitions. For each pre-selected value 532 of λ , nine models were fit, each using eight of the partitions as the training set and the ninth for 533 prediction. The mean partial likelihood over the nine models was then calculated. The model 534 using the λ that minimised this was chosen to evaluate on the test set. Nine-fold CV was used 535 to balance the advantages provided by using a greater number of folds with the limitations of 536 the number of cases in each fold as well as required computation time. In addition, individuals 537 belonging to the same family were assigned to the same fold and each contained a similar 538 number of cases to avoid folds with too few cases. 539

540

541 Random Forest

Random forest [25] is an ensemble machine learning model that estimates a function by averaging the output from a set of independently trained decision trees. During model fitting, each tree is built using a different subset of the variables and the training set to prevent individual trees from overfitting to the whole dataset. In addition, random survival forests adapts the original method to incorporate right-censored time-to-event data [23].

The hyperparameters corresponding to the number of trees (ntrees), the number of variables considered at each tree split (mtry) and the minimum terminal node size (nodesize) were selected using a grid-search CV method. **Supplementary Table 13** shows the set of values that were considered for each hyperparameter. The R package randomForestSRC (version 2.11.0) [27] was used for fitting random survival forests via *MethylPipeR*.

552

553 Bayesian Additive Regression Trees

Bayesian Additive Regression Trees (BART) [26] is a nonparametric method that estimates a
function as a sum over a set of regression trees. BART incorporates the ability to model both
additive and interaction effects and has shown high predictive performance in comparison with
similar methods. To reduce overfitting and model uncertainty in parameters and predictions,
BART uses prior distributions over tree-related parameters. Posterior estimates are obtained in
a Bayesian framework through Markov Chain Monte Carlo (MCMC).

A variant of BART for survival analysis [24] was used for 10-year onset prediction. 1,000 posterior samples for model parameters were kept after 500 burn-in samples. These were used to generate 10-year survival probabilities on the test set. This resulted in 1,000 survival

probabilities for each individual in the test set, the mean of which was used as their survival prediction. MCMC convergence was assessed using Geweke's diagnostic (gewekediag function in the BART R package). This was calculated on the BART output (yhat.test with t<=10 [24]) for the 1,000 posterior samples using 30 randomly chosen individuals in the test set. Most Z-values (77%) fell within the interval [-1.96, 1.96] suggesting convergence.

568 Due to the computation time requirements of MCMC sampling and the apparent robustness of 569 BART to hyperparameter misspecification [26], the sBART model was run with 570 hyperparameters set to default. This was performed using the R package BART (version 2.9) 571 [28] via *MethylPipeR*.

572

573 Validation of Best Performing Model in KORA S4

The present analyses are based on a subsample of the participants of the KORA S4 study. 574 575 KORA (Cooperative Health Research in the Region of Augsburg) is a research platform performing population-based surveys and subsequent follow-ups in the region of Augsburg in 576 577 Southern Germany [46]. Participants were of German nationality, aged between 25-74 years, 578 50% female, and sampled from the population registers in the study area where main place of residence was: Ausburg city town, county Ausburg or county Aichach-Friedberg. Each 579 participant completed a health questionnaire, providing details on health status and medication. 580 581 Blood samples were also taken for assaying of omics data. KORA S4 participants were recruited between 25/10/1999-28/04/2001. This study used a subsample of the 1,451 582 participants of the KORA S4 study with DNAm and incident T2D data available and no 583 prevalent diabetes at baseline. 584

The best performing model selected for the Generation Scotland cohort (Cox PH lasso) was
used for prediction of incident T2D in the KORA S4 cohort.

For diabetes morbidity, the data are limited to a follow-up of 10 years - starting from KORA S4 recruitment. For incident T2D all prevalent diabetics as well all other diabetes types except T2D cases are excluded. Age, BMI, hypertension, sex as well as self-reported family (mother or father) history of T2D were taken at the baseline of KORA S4. BMI was calculated as the individual's weight in kg divided by the square of their height in metres.

592

593 EpiScore Prediction of Ongoing Symptomatic COVID-19/Hospitalisation

Self-reported COVID-19 phenotypes were available in a subset of individuals from the 594 Generation Scotland DNA methylation sample who had also participated in the CovidLife 595 surveys (n=2,399) [33]. Ongoing symptomatic COVID-19 phenotypes were ascertained from 596 597 CovidLife survey 3, (n=1,802 Generation Scotland participants with DNAm profiled), where participants were asked about the total overall time they experienced symptoms in their 598 first/only episode of illness, as well as the whole of their COVID-19 illness. Ongoing 599 symptomatic COVID-19 was defined here as symptoms persisting for at least 4 weeks from 600 infection and is correct as of February 2021, when the survey 3 was administered. 601 Hospitalisation information, derived from the Scottish Morbidity Records (SMR01), was used 602 to obtain COVID-19 hospital admissions using ICD10 codes U07.1 (lab-confirmed COVID-603 19 diagnosis), and U07.2 (clinically-diagnosed COVID-19). Hospitalisation data is correct as 604 of February 2021. Logistic regression was used to assess the predictive performance of the 605 T2D EpiScores in relation to ongoing symptomatic COVID-19 and severe COVID-19 (i.e. 606 hospitalisation), adjusting for the standard risk factors and incident T2D before a positive 607 608 COVID-19 test.

609

Figure 1. The prediction pipeline and functionality provided in *MethylPipeR*



- **Figure 2.** ROC and PR curves for the full models with Cox PH Lasso, Random Survival
- 616 Forest and Survival BART direct EpiScores.
- 617

618

Receiver Operating Characteristic





- Figure 3. Confusion matrix plot of true/false positives/negatives for the risk factors only and 621
- full model in the Generation Scotland test dataset. (Full model uses direct and composite 622
- protein EpiScores from Cox PH Lasso.) 623



False positives

True negatives





625

628	Table 1. Summary information for the Generation Scotland training and test sets. Summary
629	information is mean (SD) or n (%).

	Training		Test	
	Cases	Controls	Cases	Controls
n	374	9461	252	4526
Time-to-event (Years to Onset or Censoring)	5.7 (3.4)	11.1 (1.8)	5.9 (3.4)	11.3 (1.7)
Age (Onset or Censoring)	61.2 (10.7)	58.1 (14.6)	60.4 (9.4)	59.2 (13.9)
Sex (Male)	184 (49.2)	3903 (41.3)	133 (52.8)	1681 (37.1)
BMI (kg/m ²)	31.7 (5.7)	26.3 (4.8)	32.2 (6.2)	26.5 (5.0)
Self-reported Parent or Sibling Diabetes	137 (36.6)	1553 (16.4)	105 (41.7)	858 (19.0)
Self-reported Hypertension	117 (31.3)	1022 (10.8)	90 (35.7)	575 (12.7)

633

Supplementary Figure 1. Preprocessing steps for Generation Scotland with number of 634 individuals/cases and controls after each step. 635



medRxiv preprint doi: https://doi.org/10.1101/2021.11.19.21266469; this version posted August 1, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY 4.0 International license .

- 638 Supplementary Figure 2. Calibration plots for the full model (risk factors + composite
- protein EpiScore + Cox PH lasso direct EpiScore) (top-left) and the risk factors only model 639
- (bottom-left). The grey area shows 95% confidence intervals calculated from 2000 bootstrap 640
- samples. The ideal calibration line (observed = predicted) is shown in red. The histogram 641 shows the distribution of predicted probabilities. The wider confidence intervals at higher 642
- predicted probabilities are due to the small number of predictions in those ranges. Most 643
- predictions are low in the probability range, emphasised in the zoomed-in plots (top-right and 644
- bottom-right). 645



646

647

648

650 **Supplementary Figure 3.** An example from the *MethylPipeR-UI* Shiny app.



651

653 **References**

- Saeedi, P., et al., *Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas.* Diabetes research and clinical practice, 2019. **157**: p. 107843.
- 657 2. Gregg, E.W., N. Sattar, and M.K. Ali, *The changing face of diabetes complications.* The lancet 658 Diabetes & endocrinology, 2016. **4**(6): p. 537-547.
- 6593.Biessels, G.J. and F. Despa, Cognitive decline and dementia in diabetes mellitus: mechanisms660and clinical implications. Nature Reviews Endocrinology, 2018. 14(10): p. 591-604.
- McGurnaghan, S.J., et al., *Risks of and risk factors for COVID-19 disease in people with diabetes: a cohort study of the total population of Scotland.* The Lancet Diabetes & Endocrinology, 2021. 9(2): p. 82-93.
- Lee, C.G., et al., *Effect of metformin and lifestyle interventions on mortality in the diabetes prevention program and diabetes prevention program outcomes study.* Diabetes care, 2021.
 44(12): p. 2775-2782.
- 667 6. Keng, M.J., et al., Impact of achieving primary care targets in type 2 diabetes on health
 668 outcomes and healthcare costs. Diabetes, Obesity and Metabolism, 2019. 21(11): p. 2405669 2412.
- 670 7. Collins, G.S., et al., *Developing risk prediction models for type 2 diabetes: a systematic review*671 *of methodology and reporting.* BMC medicine, 2011. 9(1): p. 1-14.
- 672 8. McCartney, D.L., et al., *Epigenetic prediction of complex traits and death*. Genome biology,
 673 2018. **19**(1): p. 1-11.
- 674 9. Gadd, D.A., et al., *Epigenetic scores for the circulating proteome as tools for disease prediction*.
 675 Elife, 2022. **11**: p. e71802.
- 67610.Cardona, A., et al., Epigenome-wide association study of incident type 2 diabetes in a British677population: EPIC-Norfolk study. Diabetes, 2019. 68(12): p. 2315-2326.
- Meeks, K.A., et al., *Epigenome-wide association study in whole blood on type 2 diabetes among sub-Saharan African individuals: findings from the RODAM study.* International journal
 of epidemiology, 2019. 48(1): p. 58-70.
- Walaszczyk, E., et al., DNA methylation markers associated with type 2 diabetes, fasting
 glucose and HbA 1c levels: a systematic review and replication in a case–control sample of the
 Lifelines study. Diabetologia, 2018. 61(2): p. 354-368.
- 68413.Al Muftah, W.A., et al., Epigenetic associations of type 2 diabetes and BMI in an Arab685population. Clinical epigenetics, 2016. 8(1): p. 1-10.
- 686 14. Chambers, J.C., et al., *Epigenome-wide association of DNA methylation markers in peripheral*687 *blood from Indian Asians and Europeans with incident type 2 diabetes: a nested case-control*688 *study.* The lancet Diabetes & endocrinology, 2015. **3**(7): p. 526-534.
- 15. Nakatochi, M., et al., *Epigenome-wide association of myocardial infarction with DNA methylation sites at loci related to cardiovascular disease*. Clinical epigenetics, 2017. 9(1): p.
 1-9.
- Wang, X., et al., An epigenome-wide study of obesity in African American youth and young
 adults: novel findings, replication in neutrophils, and relationship with gene expression. Clinical
 epigenetics, 2018. 10(1): p. 1-9.
- Wahl, S., et al., *Epigenome-wide association study of body mass index, and the adverse outcomes of adiposity.* Nature, 2017. 541(7635): p. 81-86.
- Haw, J.S., et al., Long-term sustainability of diabetes prevention approaches: a systematic *review and meta-analysis of randomized clinical trials.* JAMA internal medicine, 2017. 177(12):
 p. 1808-1817.
- 19. Collins, G.S., et al., *Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement.* Journal of British Surgery, 2015.
 102(3): p. 148-158.

medRxiv preprint doi: https://doi.org/10.1101/2021.11.19.21266469; this version posted August 1, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY 4.0 International license .

- 703 20. Smith, B.H., et al., Cohort Profile: Generation Scotland: Scottish Family Health Study (GS: SFHS). 704 The study, its participants and their potential for genetic research on health and illness. 705 International journal of epidemiology, 2013. 42(3): p. 689-700.
- 706 21. Simon, N., et al., Regularization paths for Cox's proportional hazards model via coordinate 707 descent. Journal of statistical software, 2011. 39(5): p. 1.
- 708 22. Friedman, J., T. Hastie, and R. Tibshirani, Regularization paths for generalized linear models 709 via coordinate descent. Journal of statistical software, 2010. 33(1): p. 1.
- 710 23. Ishwaran, H., et al., Random survival forests. Annals of Applied Statistics, 2008. 2(3): p. 841-711 860.
- 712 24. Sparapani, R.A., et al., Nonparametric survival analysis using Bayesian additive regression 713 trees (BART). Statistics in medicine, 2016. 35(16): p. 2741-2753.
- 714 25. Breiman, L., Random forests. Machine learning, 2001. 45(1): p. 5-32.
- 715 Chipman, H.A., E.I. George, and R.E. McCulloch, BART: Bayesian additive regression trees. The 26. 716 Annals of Applied Statistics, 2010. 4(1): p. 266-298.
- 717 27. Ishwaran, H. and U. Kogalur, Fast unified random forests for survival, regression, and 718 classification (RF-SRC). R package version, 2019. 2(1).
- 719 28. Sparapani, R., C. Spanbauer, and R. McCulloch, Nonparametric machine learning and efficient 720 computation with bayesian additive regression trees: the BARTR package. Journal of Statistical 721 Software, 2021. 97(1): p. 1-66.
- 722 29. Saito, T. and M. Rehmsmeier, The precision-recall plot is more informative than the ROC plot 723 when evaluating binary classifiers on imbalanced datasets. PloS one, 2015. 10(3): p. 724 e0118432.
- 725 30. Battram, T., et al., The EWAS Catalog: a database of epigenome-wide association studies. 726 2021.
- 727 Saffari, A., et al., Estimation of a significance threshold for epigenome-wide association 31. 728 *studies.* Genetic epidemiology, 2018. **42**(1): p. 20-33.
- 729 Wichmann, H.-E., et al., KORA-gen-resource for population genetics, controls and a broad 32. 730 spectrum of disease phenotypes. Das Gesundheitswesen, 2005. 67(S 01): p. 26-30.
- 731 33. Fawns-Ritchie, C., et al., CovidLife: a resource to understand mental health, well-being and 732 behaviour during the COVID-19 pandemic in the UK. Wellcome Open Research, 2021. 6(176): 733 p. 176.
- 734 Shah, W., et al., Managing the long term effects of covid-19: summary of NICE, SIGN, and RCGP 34. 735 *rapid guideline.* bmj, 2021. **372**.
- 736 Ekoe, J.-M., R. Goldenberg, and P. Katz, Screening for diabetes in adults. Canadian journal of 35. 737 diabetes, 2018. 42: p. S16-S19.
- 738 36. Van Calster, B., et al., Calibration: the Achilles heel of predictive analytics. BMC medicine, 2019. 739 17(1): p. 1-7.
- 740 Demerath, E.W., et al., Epigenome-wide association study (EWAS) of BMI, BMI change and 37. 741 waist circumference in African American adults identifies multiple replicated loci. Human 742 molecular genetics, 2015. 24(15): p. 4464-4479.
- 743 38. Mendelson, M.M., et al., Association of body mass index with DNA methylation and gene 744 expression in blood cells and relations to cardiometabolic disease: a Mendelian randomization 745 approach. PLoS medicine, 2017. 14(1): p. e1002215.
- 746 39. Sayols-Baixeras, S., et al., Identification and validation of seven new loci showing differential 747 DNA methylation related to serum lipid profile: an epigenome-wide approach. The REGICOR 748 study. Human molecular genetics, 2016. 25(20): p. 4556-4565.
- 749 40. Braun, K.V., et al., Epigenome-wide association study (EWAS) on lipids: the Rotterdam Study. 750 Clinical epigenetics, 2017. 9(1): p. 1-11.
- 751 41. Kriebel, J., et al., Association between DNA methylation in whole blood and measures of 752 glucose metabolism: KORA F4 study. PloS one, 2016. 11(3): p. e0152314.

- 753 42. Lee, J.D., et al., Exact post-selection inference, with application to the lasso. The Annals of Statistics, 2016. 44(3): p. 907-927. 754
- Taylor, J. and R. Tibshirani, Post-selection inference for-penalized likelihood models. Canadian 755 43. 756 Journal of Statistics, 2018. 46(1): p. 41-61.
- Lin, D., On the Breslow estimator. Lifetime data analysis, 2007. 13(4): p. 471-480. 757 44.
- 758 45. Ridgeway, G., Generalized Boosted Models: A guide to the gbm package. Update, 2007. 1(1): 759 p. 2007.
- Holle, R., et al., KORA-a research platform for population based health research. Das 760 46. Gesundheitswesen, 2005. 67(S 01): p. 19-25. 761